Intra-Cellular Surges On First Phase III Schizophrenia Data

Intra-Cellular Therapies saw its share price climb 86.9% to close at a new peak of $48.79 on Sept. 16 after the company reported that ITI-007 showed a potentially differentiated safety profile relative to approved antipsychotic drugs in the first of two Phase III schizophrenia clinical trials.

Intra-Cellular Therapies saw its share price climb 86.9% to close at a new peak of $48.79 on Sept. 16 after the company reported that ITI-007 showed a potentially differentiated safety profile relative to approved antipsychotic drugs in the first of two Phase III schizophrenia clinical trials.

New York-based Intra-Cellular is pursuing a first-line indication for the treatment of schizophrenia with ITI-007, which combines serotonin 5-HT2A receptor...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category